Cargando…
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease
Charcot–Marie–Tooth disease (CMT) is the most common inherited peripheral neuropathy, with an estimated prevalence of 1 in 2500. The degeneration of motor and sensory nerve axons leads to motor and sensory symptoms that progress over time and have an important impact on the daily life of these patie...
Autores principales: | Benoy, Veronick, Vanden Berghe, Pieter, Jarpe, Matthew, Van Damme, Philip, Robberecht, Wim, Van Den Bosch, Ludo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398982/ https://www.ncbi.nlm.nih.gov/pubmed/27957719 http://dx.doi.org/10.1007/s13311-016-0501-z |
Ejemplares similares
-
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease
por: Benoy, Veronick, et al.
Publicado: (2018) -
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
por: Guo, Wenting, et al.
Publicado: (2017) -
Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice
por: Herdewyn, Sarah, et al.
Publicado: (2014) -
Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy
por: Mo, Zhongying, et al.
Publicado: (2018) -
Mutation in PNKP presenting initially as axonal Charcot-Marie-Tooth disease
por: Pedroso, José Luiz, et al.
Publicado: (2015)